The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals.
Patricia G SynnottDominic VoehlerDaniel E EnrightStacey KowalDaniel A OllendorfPublished in: Applied health economics and health policy (2022)
Major HTA organizations do not recognize novelty as an explicit value criterion, although drugs with novel characteristics may receive special consideration. There is an opportunity for organizations to codify their approach to evaluating novelty in value assessment.